Complex Oncological Center Plovdiv EOOD
- Address
- lock Available on a paid plan
Solid Tumor Oncology
The Complex Oncological Center Plovdiv EOOD conducts extensive research on advanced solid tumors, aiming to evaluate innovative targeted and immunotherapy approaches that may improve survival and quality of life for patients.
- Advanced breast cancer
- Advanced non‑small cell lung cancer
- Metastatic ovarian cancer
- Colorectal cancer with BRAF V600E mutation
- Renal cell carcinoma
- Muscle‑invasive bladder cancer
With 41 ongoing trials and a team of 12 investigators, the site is a hub for testing new therapies across multiple solid tumor types.
Hematologic Malignancies
Researchers at the center focus on blood‑related cancers, exploring novel agents and combination regimens to enhance treatment efficacy for patients with aggressive disease.
- Acute myeloid leukemia
- Myelodysplastic syndrome
- Chronic myelomonocytic leukemia
- Diffuse large B‑cell lymphoma
- Follicular lymphoma
- Acute lymphoblastic leukemia
The program evaluates emerging targeted therapies and immunomodulators to address unmet needs in hematologic oncology.
Prostate Cancer Research
The department advances prostate cancer care by testing hormonal strategies and DNA‑repair targeting agents, seeking to prolong progression‑free survival in both castration‑sensitive and castration‑resistant settings.
- Metastatic castration‑sensitive prostate cancer
- Castration‑resistant prostate cancer
- PTEN‑deficient metastatic hormone‑sensitive prostate cancer
- HRR‑mutated prostate cancer
- High tumor‑load prostate cancer
- Prostate cancer with PTEN loss
Ongoing trials evaluate combinations such as PARP inhibitors with androgen deprivation therapy to improve outcomes.
Gynecologic Oncology
Studies target ovarian, fallopian tube, peritoneal, and endometrial cancers, aiming to refine the use of PARP inhibitors, antibody‑drug conjugates, and immunotherapy for better disease control.
- BRCA‑mutated ovarian cancer
- Platinum‑sensitive relapsed ovarian cancer
- High‑grade serous ovarian carcinoma
- Endometrial cancer
- Uterine cancer
- Ovarian cancer with HRD
The site integrates biomarker‑driven trials to personalize therapy for women with gynecologic malignancies.
Lung Cancer Innovation
A dedicated program investigates both non‑small cell and small‑cell lung cancers, focusing on KRAS‑mutated, HER2‑positive, and PD‑L1‑high tumors to assess novel targeted‑immunotherapy combos.
- KRAS‑mutated non‑small cell lung cancer
- HER2‑positive NSCLC
- Extensive‑stage small‑cell lung cancer
- Limited‑stage small‑cell lung cancer
- PD‑L1 high NSCLC
- NSCLC with BRAF mutation
Trials assess agents such as KRAS inhibitors, HER2‑directed antibodies, and checkpoint inhibitors to extend survival.
Renal and Urinary Tract Oncology
Research includes renal cell carcinoma and urothelial carcinoma, evaluating checkpoint inhibitors and combination regimens to improve response rates in these malignancies.
- Renal cell carcinoma
- Locally advanced urothelial carcinoma
- Metastatic urothelial carcinoma
- Kidney cancer
- Bladder cancer
The program explores synergistic effects of immunotherapy with targeted agents and chemotherapy.
Head and Neck & Skin Cancer
The center evaluates therapies for head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma, seeking to enhance response through immunotherapy and novel biologics.
- Head and neck squamous cell carcinoma
- Cutaneous squamous cell carcinoma
- Advanced skin cancer
- HPV‑related oropharyngeal cancer
- Recurrent head and neck cancer
Ongoing studies compare checkpoint blockade alone versus combined with investigational agents.
Metabolic and Physiological Research
Beyond tumor‑focused trials, the site investigates metabolic, nutritional, and physiological phenomena that influence cancer progression and patient resilience.
- Cancer‑associated cachexia
- Metabolic alterations in tumor microenvironment
- Nutritional support in oncology
- Genetic biomarkers for therapy response
- Microbiome influence on immunotherapy
- Physiological monitoring of treatment tolerance
These studies aim to optimize supportive care and identify predictive markers that guide personalized treatment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 12 therapeutic areas and 15 of 105 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 103 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1Pfizer Inc.3active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.11trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Complex Oncological Center Plovdiv EOOD
lock Showing 1 of 50 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641) | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Aug 2019 | Aug 2025 |
IMP list
lock Showing 1 of 105 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 10 | Unknown | 2019-08-23 | 2025-06-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.